[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352130-105":59,"doc-detail-352130-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","small-cell-lung-cancer-biology-translational-science-and-clinical-innovation","Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation","","Small-cell lung cancer (SCLC) is a highly aggressive malignancy marked by rapid metastasis and eventual resistance to platinum chemotherapy and immunotherapy. Despite decades of investigation using mechanistic mouse models, therapeutic advances were limited. Recent years have accelerated drug development, including FDA approval of tarlatamab, and multiple trials exploring new first-line and later-line combinations. This review summarizes SCLC biology, molecular landscape, and multidisciplinary management across limited- and extensive-stage disease.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/small-cell-lung-cancer-biology-translational-science-and-clinical-innovation/352130/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/small-cell-lung-cancer-biology-translational-science-and-clinical-innovation/352130.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What makes small-cell lung cancer (SCLC) clinically difficult to treat?","Question",{"text":113,"@type":114},"SCLC develops rapid metastases and later develops resistance to platinum chemotherapy and immunotherapy, leading to poor outcomes despite ongoing investigation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is the limited-stage vs extensive-stage framework for SCLC?",{"text":118,"@type":114},"SCLC is commonly classified into limited stage (LS-SCLC; stage I–III with M0, treated with definitive radiation) and extensive stage (ES-SCLC; stage IV or selected T3–T4 cases with extensive spread not safely encompassed by radiation).",{"name":120,"@type":111,"acceptedAnswer":121},"How does this review connect SCLC biology to emerging therapies?",{"text":122,"@type":114},"It links the cellular and molecular landscape—including molecular subtypes and diagnostic markers—to how novel therapeutics and clinical trial strategies are being designed, and it highlights key research questions for the coming decade.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352130,1790194734,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Drugs (2026) 86:1513–1533  \n[https://doi.org/10.1007/s40265-026-02353-7](https://doi.org/10.1007/s40265-026-02353-7)  \nSmall‑Cell Lung Cancer: Biology, Translational Science and Clinical Innovation  \nShrey Sindhwani1 · Miles Thomas1 · Kanika Gehlaut2 · Harveen Kaur1 · Waqas Haque1 · Aditya Juloori3 ·  \nNoura J. Choudhury1  \nReceived: 16 February 2026 / Accepted: 27 May 2026 / Published online: 7 August 2026 © The Author(s) 2026  \nAbstract  \nSmall-cell lung cancer (SCLC) is widely considered one of the most aggressive human malignancies, characterized by development of rapid metastases and eventual resistance to platinum chemotherapy and immunotherapy. For decades, despite rigorous scientific investigation and well-established mouse models providing a basis for mechanistic understanding, there were limited therapeutic advances for SCLC. The past decade has seen reinvigoration of drug development for SCLC as well as US Food and Drug Administration (FDA) approval of tarlatamab, a bispecific T-cell engager with unprecedented survival advantage in this recalcitrant disease. Multiple other promising clinical trials in the first and later-line settings are underway that seek to challenge standards of first-line chemoimmunotherapy, investigate combination treatments in the later line, and introduce T-cell engagers earlier in treatment. This review provides a comprehensive primer on the biology and molecular landscape of SCLC, in the context of how both shape ongoing investigational strategies. A broad overview of established multidisciplinary management of both limited-stage and extensive-stage SCLC is discussed to provide understanding of how the next decade is likely to bring significant clinical gains as emerging therapeutics seek to redefine the management of SCLC and build upon novel advances.  \n* Noura J. Choudhury [noura.choudhury@bsd.uchicago.edu](noura.choudhury@bsd.uchicago.edu)  \n1 Department of Medicine, University of Chicago, Chicago, IL, USA  \n2 Department of Radiation Oncology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, UP, India  \n3 Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA  \n1 Overview  \nIn the United States, lung cancer is the third most common cancer type by incidence and the leading cause of cancerrelated mortality [1] . Small-cell lung cancer (SCLC), an aggressive subtype of lung cancer, accounts for roughly 13% of lung cancer cases [2–4]. Cigarette smoking is the primary risk factor for SCLC, accounting for roughly 95% of cases [5] . Between 2000 and 2020, the annual incidence of SCLC decreased from 9 cases per 100,000 to 4.6 cases per 100,000, corresponding to declining rates of smoking [3] . A small percentage (2-3%) of SCLC cases occur in patients with limited smoking history, including those with transformed SCLC [6] . Treatment strategies and outcomes for SCLC depend on stage, with SCLC using a binary classification system of limited stage (LS-SCLC) or extensive stage (ESSCLC) disease. The current National Comprehensive Cancer Network (NCCN) guidelines define LS-SCLC as stage I–III (T any, N any, M0), which can be safely treated with definitive radiation therapy. ES-SCLC is defined as stage IV, or as T3–T4 disease with extensive lung nodules or nodal involvement that cannot be safely encompassed in a radiation plan [7] . Innovative treatment strategies and novel therapeutics are crucial because nearly 70% of SCLC cases are metastatic  \nat the time of diagnosis [1, 3] . Despite recent progress and an expanding number of investigative therapies, outcomes remain poor for patients with SCLC, particularly in therelapsed setting [2] . In this review, we summarize current understanding and highlight challenges in SCLC management. The review also explores how improved understanding of the cellular biology of SCLC has informed novel therapeutics, clinical trial strategies, and translation of upcoming therapeutic entities. Lastly, we outline the major re","cbCaiqFDE3lqHXFc","https://ap.wps.com/l/cbCaiqFDE3lqHXFc","pdf",1148998,21,"English","# Abstract\n# Overview\n## Epidemiology and staging\n# Biology of Small-Cell Lung Cancer (SCLC)\n## Pathological Features","[{\"question\":\"What makes small-cell lung cancer (SCLC) clinically difficult to treat?\",\"answer\":\"SCLC develops rapid metastases and later develops resistance to platinum chemotherapy and immunotherapy, leading to poor outcomes despite ongoing investigation.\"},{\"question\":\"What is the limited-stage vs extensive-stage framework for SCLC?\",\"answer\":\"SCLC is commonly classified into limited stage (LS-SCLC; stage I–III with M0, treated with definitive radiation) and extensive stage (ES-SCLC; stage IV or selected T3–T4 cases with extensive spread not safely encompassed by radiation).\"},{\"question\":\"How does this review connect SCLC biology to emerging therapies?\",\"answer\":\"It links the cellular and molecular landscape—including molecular subtypes and diagnostic markers—to how novel therapeutics and clinical trial strategies are being designed, and it highlights key research questions for the coming decade.\"}]","Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation | PDF",1790097828,53,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e73c97aa09d750649ca6d4cd30e77be5.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cafa265430a6c3d246eea56e1c38c5ce.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/044de2f266b564e34a3837a9722c7209.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c26a89a1797f8836459cf7542d7723fb.webp",980,1301]